These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31674290)

  • 21. QcrB inhibition as a potential approach for the treatment of tuberculosis: A review of recent developments, patents, and future directions.
    Imran M; Abida ; Alotaibi NM; Thabet HK; Alruwaili JA; Asdaq SMB; Eltaib L; Alshehri A; Alsaiari AA; Almehmadi M; Alshammari ABH; Alshammari AM
    J Infect Public Health; 2023 Jun; 16(6):928-937. PubMed ID: 37086552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of potent L,D-transpeptidase 5 inhibitors for Mycobacterium tuberculosis as potential anti-TB leads: virtual screening and molecular dynamics simulations.
    Sabe VT; Tolufashe GF; Ibeji CU; Maseko SB; Govender T; Maguire GEM; Lamichhane G; Honarparvar B; Kruger HG
    J Mol Model; 2019 Oct; 25(11):328. PubMed ID: 31656981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
    Saxena S; Abdullah M; Sriram D; Guruprasad L
    J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
    Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
    J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
    Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probing the structure of Mycobacterium tuberculosis MbtA: model validation using molecular dynamics simulations and docking studies.
    Maganti L; Open Source Drug Discovery Consortium ; Ghoshal N
    J Biomol Struct Dyn; 2014; 32(2):273-88. PubMed ID: 23527569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel and potent InhA inhibitors by an
    Hanwarinroj C; Phusi N; Kamsri B; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
    Future Med Chem; 2022 May; 14(10):717-729. PubMed ID: 35485258
    [No Abstract]   [Full Text] [Related]  

  • 28. Inhibitor binding studies of
    Mallavarapu BD; Abdullah M; Saxena S; Guruprasad L
    J Biomol Struct Dyn; 2019 Sep; 37(14):3751-3763. PubMed ID: 30239262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
    Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the interaction mechanism between potential inhibitor and multi-target Mur enzymes of mycobacterium tuberculosis using molecular docking, molecular dynamics simulation, principal component analysis, free energy landscape, dynamic cross-correlation matrices, vector movements, and binding free energy calculation.
    Kumari M; Singh R; Subbarao N
    J Biomol Struct Dyn; 2022; 40(24):13497-13526. PubMed ID: 34662260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico and in vitro study of Mycobacterium tuberculosis H37Rv uncharacterized protein (RipD): an insight on tuberculosis therapeutics.
    Arega AM; Dhal AK; Nayak S; Mahapatra RK
    J Mol Model; 2022 May; 28(6):171. PubMed ID: 35624324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Antimycobacterial Agent Using In Silico Virtual Screening, ADME Prediction, Docking, and Molecular Dynamics Simulations Approach.
    Tripathy S; Sahu SK; Azam MA; Jupudi S; Gupta VK; Sharma S
    Curr Comput Aided Drug Des; 2021; 17(6):806-816. PubMed ID: 32748754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.
    Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK
    J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug targeted virtual screening and molecular dynamics of LipU protein of Mycobacterium tuberculosis and Mycobacterium leprae.
    Kaur G; Pandey B; Kumar A; Garewal N; Grover A; Kaur J
    J Biomol Struct Dyn; 2019 Mar; 37(5):1254-1269. PubMed ID: 29557724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
    Cleghorn LAT; Ray PC; Odingo J; Kumar A; Wescott H; Korkegian A; Masquelin T; Lopez Moure A; Wilson C; Davis S; Huggett M; Turner P; Smith A; Epemolu O; Zuccotto F; Riley J; Scullion P; Shishikura Y; Ferguson L; Rullas J; Guijarro L; Read KD; Green SR; Hipskind P; Parish T; Wyatt PG
    J Med Chem; 2018 Aug; 61(15):6592-6608. PubMed ID: 29944372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome
    Gries R; Dal Molin M; Chhen J; van Gumpel E; Dreyer V; Niemann S; Rybniker J
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0025123. PubMed ID: 37358461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based identification of natural compound inhibitor against
    Lata S; Akif M
    J Biomol Struct Dyn; 2021 Aug; 39(12):4480-4489. PubMed ID: 32567497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Copper transporter protein (MctB) as a therapeutic target to elicit antimycobacterial activity against tuberculosis.
    Dwivedi M; Jose S; Gupta M; Devi SS; Raj R; Kumar D
    J Biomol Struct Dyn; 2024 Jul; 42(10):5334-5348. PubMed ID: 37340670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening of Anti-mycobacterial Phytochemical Compounds for Potential Inhibitors against Mycobacterium Tuberculosis Isocitrate Lyase.
    Tiwari A; Kumar A; Srivastava G; Sharma A
    Curr Top Med Chem; 2019; 19(8):600-608. PubMed ID: 30836915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virtual screening and free energy estimation for identifying Mycobacterium tuberculosis flavoenzyme DprE1 inhibitors.
    Niranjan Kumar ; Srivastava R; Prakash A; Lynn AM
    J Mol Graph Model; 2021 Jan; 102():107770. PubMed ID: 33065513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.